J Korean Ophthalmol Soc > Volume 51(6); 2010 > Article
Journal of the Korean Ophthalmological Society 2010;51(6):842-848.
DOI: https://doi.org/10.3341/jkos.2010.51.6.842    Published online June 15, 2010.
Long-term Effect of Panretinal Photocoagulation Combined With Intravitreal Bevacizumab in High-risk Proliferative Diabetic Retinopathy.
Jun Ho Choi, Sung Jin Lee, Kyung Seek Choi
Department of Ophthalmology, Soonchunhyang University College of Medicine, Seoul, Korea. ckseek@naver.com
고위험 증식당뇨망막병증에서 범망막광응고술과 유리체강내 베바시주맙 병합치료의 장기간 효과
최준호ㆍ이성진ㆍ최경식
Department of Ophthalmology, Soonchunhyang University College of Medicine, Seoul, Korea
Abstract
PURPOSE
To evaluate long-term effects and usefulness of combined intravitreal injection of bevacizumab and panretinal photocoagulation (PRP) in patients with high-risk proliferative diabetic retinopathy. METHODS: The authors retrospectively reviewed the records of 40 patients (40 eyes) with high-risk proliferative diabetic retinopathy who had been treated with PRP alone (laser treatment group, n=20) or intravitreal bevacizumab before PRP (combined treatment group, n=20). Changes in best corrected visual acuity (BCVA), central macular thickness (CMT) and the total area of leakage from active new vessels (NVs) were compared between the groups at one, three, and six months and at one year post-treatment. RESULTS: In the combined treatment group, CMT decreased significantly at one month (p=0.021), and the areas of active NVs decreased significantly at one month (p=0.001) and three months (p=0.014) compared to those of the laser treatment group. However, there were no differences between the two groups after three months. In the combined treatment group, elevated intraocular pressures were found in three cases after one month, and there were vitreous hemorrhages in two cases after three months. CONCLUSIONS: The combined treatment showed significant early improvements in BCVA, CMT, and NVs regression for up to three months. However, long-term follow-up and additional treatment was necessary in the patients with persistent or recurred NVs and macular edema after three months.
Key Words: Bevacizumab;High risk proliferative diabetic retinopathy (PDR);Proliferative diabetic retinopathy (PDR);Panretinal photocoagulation (PRP)


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2024 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next